Genome Sequencing: Understanding DNA Composition and Function

Written by The Life Science Feed Editorial Team · Published 6 August 2026 · Edited by Mara Voss

> Understanding the complete genetic makeup of an individual or organism is fundamental to modern medicine and biological research. The ability to sequence a genome allows for the identification of genetic variations, disease susceptibility, and potential therapeutic targets.

KEY TAKEAWAYS

- The Pivot: Advances in sequencing technologies have made comprehensive genomic analysis increasingly accessible.
- The Data: Whole-genome sequencing provides the complete nucleotide sequence of an organism's DNA, including coding and non-coding regions.
- The Action: Clinicians can utilise genomic data to inform diagnoses, predict drug responses, and guide personalised treatment strategies for patients with genetic conditions or certain cancers.

The human genome comprises approximately 3 billion base pairs of DNA, organised into 23 pairs of chromosomes.1 Each base pair consists of two complementary nucleotides: adenine (A) with thymine (T), and guanine (G) with cytosine (C). The specific sequence of these base pairs encodes the genetic instructions necessary for an organism's development and function.1 Scientists employ various methods to ascertain this sequence, with the primary goal being to read the order of A, T, C, and G along the DNA strands. This process, known as DNA sequencing, has evolved significantly since its inception.

Methods for Genomic Analysis

Early sequencing methods, such as Sanger sequencing (also known as the chain-termination method), were foundational. This technique involves creating DNA copies using modified nucleotides that terminate the replication process at specific bases.2 The resulting fragments, varying in length, are then separated by size, allowing the original sequence to be inferred. While highly accurate for shorter DNA segments, Sanger sequencing is labour-intensive and not practical for sequencing an entire genome.2

The advent of next-generation sequencing (NGS) technologies, also termed high-throughput sequencing, revolutionised genomic analysis. These methods enable the parallel sequencing of millions of DNA fragments simultaneously.3 A common NGS approach involves fragmenting the entire genome into smaller pieces, typically 100-500 base pairs in length.3 These fragments are then ligated with adapter sequences and immobilised on a solid surface, such as a flow cell. Each fragment is amplified to create clusters of identical DNA molecules. Fluorescently labelled nucleotides are then added, and a camera captures the light emitted as each nucleotide is incorporated into the growing DNA strand.3

This parallel process generates vast amounts of sequence data, which bioinformatic tools then align and assemble to reconstruct the original genomic sequence.4

Different NGS platforms exist, each with specific advantages regarding read length, accuracy, and cost. Whole-genome sequencing (WGS) aims to sequence the entire genome, providing comprehensive information about both coding and non-coding regions.5 In contrast, whole-exome sequencing (WES) focuses specifically on the exome, which comprises the protein-coding regions of the genome and accounts for approximately 1-2% of the total genome.5 WES is often preferred in clinical settings for identifying disease-causing mutations because most known pathogenic variants reside within exons.5 Targeted sequencing, another approach, focuses on specific genes or regions of interest, offering higher depth of coverage and cost-effectiveness for known genetic conditions.6

The data generated from sequencing requires sophisticated computational analysis. Bioinformatic pipelines are used to quality control the raw sequence reads, align them to a reference genome, identify variants (such as single nucleotide polymorphisms (SNPs), insertions, and deletions), and interpret their potential functional consequences.4 The accuracy of these analyses is paramount for clinical utility, with variant calling algorithms continually being refined to minimise false positives and false negatives.4

The clinical utility of genome sequencing is rapidly expanding. In oncology, WGS and WES can identify somatic mutations in tumours, guiding targeted therapies and predicting treatment response. For rare genetic diseases, sequencing can provide a definitive diagnosis, ending diagnostic odysseys and enabling personalised management strategies. Preimplantation genetic testing (PGT) and prenatal diagnosis also leverage sequencing to detect chromosomal abnormalities or monogenic disorders.

Despite its transformative potential, genome sequencing faces limitations. The interpretation of variants of uncertain significance (VUS) remains a significant challenge, often requiring further functional studies or family segregation analysis. Ethical considerations surrounding data privacy, informed consent, and the potential for incidental findings also necessitate careful navigation. Furthermore, the cost of sequencing, while decreasing, can still be a barrier to widespread adoption, particularly in resource-limited settings.

Future Directions in Genomic Medicine

The future of genome sequencing is poised for further innovation. Long-read sequencing technologies, such as Pacific Biosciences (PacBio) and Oxford Nanopore Technologies, are gaining prominence. These methods can sequence much longer DNA fragments, improving the detection of structural variants, repetitive regions, and complex rearrangements that are often missed by short-read NGS. 7 The integration of multi-omics data – including genomics, transcriptomics, proteomics, and metabolomics – promises a more holistic understanding of disease mechanisms. Artificial intelligence and machine learning algorithms are also being developed to enhance variant interpretation, predict disease risk, and personalise treatment recommendations, ultimately moving towards a truly predictive, preventive, personalised, and participatory (P4) medicine.

> **CLINICAL IMPLICATIONS**

The increasing accessibility of genomic sequencing has profound implications for clinical practice, moving beyond the realm of rare disease diagnostics into broader applications. General practitioners and specialists alike will increasingly encounter patients with genomic data, necessitating a foundational understanding of its interpretation and limitations. The challenge now lies not just in generating the sequence, but in translating complex genetic information into actionable clinical insights. For instance, pharmacogenomic testing, a direct application of sequencing, can predict individual responses to specific medications, potentially reducing adverse drug reactions and optimising treatment efficacy. However, the integration of these data into routine clinical workflows requires robust decision support systems and ongoing education for healthcare providers.
From an industry perspective, the proliferation of sequencing technologies has spurred innovation in diagnostic platforms and bioinformatics. Companies like Illumina and Thermo Fisher Scientific continue to drive down costs and increase throughput, making WGS and WES more economically viable. This competitive landscape is beneficial, but it also means clinicians must critically evaluate the performance characteristics and validation data of different commercial assays. Furthermore, the ethical considerations surrounding data privacy, incidental findings, and equitable access to genomic medicine remain significant, requiring careful policy development and patient counselling.
For patients, the promise of personalised medicine, guided by their unique genetic blueprint, offers hope for more precise diagnoses and tailored therapies, particularly in oncology and rare genetic disorders. However, the psychological impact of receiving complex genetic information, including predispositions to future diseases, cannot be underestimated. Clear communication from clinicians, supported by genetic counsellors, is essential to manage patient expectations and ensure informed decision-making. The utility of genomic data will only be fully realised when it is integrated thoughtfully into a holistic patient care model, rather than viewed as an isolated diagnostic tool.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. National Human Genome Research Institute. The Human Genome Project. Accessed October 26, 2023. https://www.genome.gov/human-genome-project
2. 2. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463-5467. doi:10.1073/pnas.74.12.5463
3. 3. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11(1):31-46.
4. 4. Goodwin S, McPherson J, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333-351. doi:10.1038/nrg.2016.49
5. 5. Rabbani B, Tekin M, Kariminejad A. Whole exome sequencing: a new approach in medical genetics. Iran J Pediatr. 2014;24(2):135-145.
6. 6. Mamanova L, Coffey AJ, Scott HS, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010;7(2):111-118. doi:10.1038/nmeth.1419

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com